Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Biosimilar Reviews Raise Questions About Differences In Asia

This article was originally published in PharmAsia News

Executive Summary

Regulators are beginning to decide on the acceptability of imitation biotech products, despite a continuing inability to fully ascertain how they differ from the brand products, or what the perceived differences actually mean

You may also be interested in...



PhRMA Urges Japan To Create Separate Regulations For Biosimilars

TOKYO - The Pharmaceutical Research and Manufacturers of America called on Japan to create a separate regulatory structure for biosimilar drugs from branded biologics, a day after the Ministry of Health, Labor and Welfare released a draft biosimilar guideline Sept. 17

PhRMA Urges Japan To Create Separate Regulations For Biosimilars

TOKYO - The Pharmaceutical Research and Manufacturers of America called on Japan to create a separate regulatory structure for biosimilar drugs from branded biologics, a day after the Ministry of Health, Labor and Welfare released a draft biosimilar guideline Sept. 17

Japan Posts Draft Guidance On Biosimilars; Seeks Public Comment

TOKYO - Japan's Ministry of Health, Labor and Welfare Sept. 17 posted draft guidance on follow-on biologics, or biosimilars, a move that could make Japan among the first group of large economies to set a safety and regulatory framework for the new copycat breed of biologic therapies

Related Content

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel